Mesoblast Company Profile (NASDAQ:MESO)

About Mesoblast

Mesoblast logoMesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MESO
  • CUSIP:
Key Metrics:
  • Previous Close: $4.31
  • 50 Day Moving Average: $5.02
  • 200 Day Moving Average: $6.26
  • 52-Week Range: $3.50 - $13.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.37
  • P/E Growth: 0.00
  • Market Cap: $325.72M
  • Outstanding Shares: 75,574,000
  • Beta: 2.9
Profitability:
  • Net Margins: -9.70%
  • Return on Equity: 7.40%
  • Return on Assets: 4.82%
Debt:
  • Current Ratio: 3.02%
  • Quick Ratio: 3.02%
Additional Links:
Companies Related to Mesoblast:

Analyst Ratings

Consensus Ratings for Mesoblast (NASDAQ:MESO) (?)
Ratings Breakdown: 3 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $8.63 (100.12% upside)

Analysts' Ratings History for Mesoblast (NASDAQ:MESO)
Show:
DateFirmActionRatingPrice TargetDetails
7/6/2016Maxim GroupReiterated RatingBuy$14.00View Rating Details
6/14/2016Credit Suisse Group AGDowngradeOutperform -> Neutral$10.00 -> $5.00View Rating Details
3/7/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$9.00 -> $10.00View Rating Details
2/25/2016Chardan CapitalReiterated RatingHoldView Rating Details
11/24/2015Ladenburg ThalmannReiterated RatingBuyView Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Mesoblast (NASDAQ:MESO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/16/2016Q216($0.06)$30.00 million$4.00 millionViewListenView Earnings Details
12/16/2015Q116($0.04)$7.50 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mesoblast (NASDAQ:MESO)
Current Year EPS Consensus Estimate: $-0.91 EPS
Next Year EPS Consensus Estimate: $-0.30 EPS

Dividends

Dividend History for Mesoblast (NASDAQ:MESO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mesoblast (NASDAQ:MESO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Mesoblast (NASDAQ:MESO)
DateHeadline
News IconBone Marrow Transplant Market Regulations and Competitive Landscape Outlook to 2026 (NASDAQ:MESO)
www.medgadget.com - September 30 at 11:21 AM
sbwire.com logoStem Cell Therapy Market Report Forecasts Impressive Growth by 2022 - Scalar Market Research (NASDAQ:MESO)
www.sbwire.com - September 29 at 11:12 AM
openpr.com logoResearch report explores the Graft Versus Host Disease GvHD Treatment Market for the forecast period, 2016-2026 (NASDAQ:MESO)
www.openpr.com - September 28 at 11:03 AM
News IconGlobal Regenerative Therapies Market is Expected to Reach US$ 18 Bn by 2022 – Persistence Market Research (NASDAQ:MESO)
www.abnewswire.com - September 27 at 6:00 PM
News IconGUIDELINES FOR TRANSFUSION OF (NASDAQ:MESO)
docplayer.net - September 27 at 10:43 AM
News IconGraft Versus Host Disease GvHD Treatment Market Global Industry Analysis and Forecast Till 2026 (NASDAQ:MESO)
www.emailwire.com - September 24 at 5:37 PM
News IconConsensus Take: Mesoblast limited (ADR) (NASDAQ:MESO) Earnings & Ratings Watch - Frisco Fastball (NASDAQ:MESO)
friscofastball.com - September 22 at 5:50 PM
fool.com logoThis high-risk sector is one ALL new investors should avoid - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - September 22 at 10:53 AM
investing.com logoMesoblast: Tightening Focus To Extend Runway - Investing.com (NASDAQ:MESO)
www.investing.com - September 22 at 10:53 AM
fool.com logoThis high-risk sector is one ALL new investors should avoid (NASDAQ:MESO)
www.fool.com.au - September 21 at 10:13 AM
investing.com logoMesoblast: Tightening Focus To Extend Runway (NASDAQ:MESO)
www.investing.com - September 21 at 10:13 AM
capitalcube.com logoETF’s with exposure to Mesoblast Ltd. : September 19, 2016 (NASDAQ:MESO)
www.capitalcube.com - September 19 at 10:38 AM
investing.com logoAustralia stocks higher at close of trade; S&P/ASX 200 up 1.00% - Investing.com (NASDAQ:MESO)
www.investing.com - September 18 at 10:28 AM
fool.com logoHere’s why these 4 ASX shares dropped today (NASDAQ:MESO)
www.fool.com.au - September 16 at 9:34 AM
News IconInvest only in organisations that have female board members? Excellent idea - Women's Agenda (NASDAQ:MESO)
www.womensagenda.com.au - September 14 at 10:23 AM
News IconWhat is the Street Saying About Mesoblast limited (ADR) (NASDAQ:MESO)? - Frisco Fastball (NASDAQ:MESO)
friscofastball.com - September 14 at 10:23 AM
openpr.com logoStem Cells Market to Cross US$ 297 Billion by 2022 (NASDAQ:MESO)
www.openpr.com - September 12 at 10:45 AM
fool.com logoASX 200 shines gold: 13 shares you should have been watching - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - September 9 at 10:50 AM
publicnow.com logoChange of Melbourne Registry Address Notification (NASDAQ:MESO)
www.publicnow.com - September 9 at 10:50 AM
newsmaker.com.au logoBone Marrow Transplant Market 2016 Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast to 2022 (NASDAQ:MESO)
www.newsmaker.com.au - September 7 at 6:17 PM
einnews.com logoBone Marrow Transplant World Market Segmentation and Major Players Analysis 2022 (NASDAQ:MESO)
www.einnews.com - September 7 at 6:17 PM
capitalcube.com logoETF’s with exposure to Mesoblast Ltd. : September 6, 2016 (NASDAQ:MESO)
www.capitalcube.com - September 6 at 6:09 PM
sbwire.com logoResearch on Graft Versus Host Disease GvHD Treatment Market 2016 and Analysis to 2026 (NASDAQ:MESO)
www.sbwire.com - September 6 at 10:50 AM
News IconMesoblast names Bill Burns as vice chairman (NASDAQ:MESO)
www.poandpo.com - September 3 at 8:14 AM
News IconLIVE BLOG Last Updated 8:04PM AEST BusinessNow: Live coverage of financial markets and companies, plus ... - The Australian (NASDAQ:MESO)
www.theaustralian.com.au - September 2 at 10:57 AM
fool.com logoHow Lithium Pair Galaxy Resources Limited and Orocobre Limited Exploded into the ASX 200 - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - September 2 at 10:57 AM
capitalcube.com logoMesoblast Ltd. :MESO-US: Earnings Analysis: 2016 By the Numbers : September 2, 2016 (NASDAQ:MESO)
www.capitalcube.com - September 2 at 10:56 AM
finance.yahoo.com logoMesoblast Appoints Bill Burns, Former Chief Executive of Roche Pharmaceuticals, as Vice Chairman (NASDAQ:MESO)
finance.yahoo.com - September 1 at 9:13 AM
News IconLIVE BLOG Last Updated 8:45PM AEST BusinessNow: Live coverage of financial markets and companies, plus ... - The Australian (NASDAQ:MESO)
www.theaustralian.com.au - August 30 at 6:07 PM
investing.com logoAustralia stocks higher at close of trade; S&P/ASX 200 up 0.32% - Investing.com (NASDAQ:MESO)
www.investing.com - August 30 at 6:07 PM
finance.yahoo.com logoMESOBLAST LTD Financials (NASDAQ:MESO)
finance.yahoo.com - August 30 at 6:07 PM
News IconGlobal Regenerative Therapies Market to reach US$ 18,429.8 Mn by 2022, Asia Pacific & Japan to Witness Highest Growth During the Forecast Period (NASDAQ:MESO)
www.medgadget.com - August 29 at 6:01 PM
fool.com logoASX 200 to rise: 13 shares you need to watch today - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - August 26 at 9:07 AM
reuters.com logoBRIEF-Mesoblast reports Q4 earnings per share $0.1278 (NASDAQ:MESO)
www.reuters.com - August 25 at 11:13 AM
benzinga.com logoMesoblast Reports Financial Results and... (NASDAQ:MESO)
www.benzinga.com - August 25 at 11:13 AM
News IconMesoblast’s MPC: Positive Results (NASDAQ:MESO)
ryortho.com - August 25 at 11:13 AM
investing.com logoMarkets Limp Towards Yellen’s Friday Speech (NASDAQ:MESO)
www.investing.com - August 25 at 11:13 AM
4-traders.com logoMesoblast : Reports on Annual and Fourth Quarter Results (NASDAQ:MESO)
www.4-traders.com - August 25 at 11:13 AM
finance.yahoo.com logoMesoblast Reports Financial Results and Operational Highlights for the Three Months and for the Year Ended 30 June 2016 (NASDAQ:MESO)
finance.yahoo.com - August 25 at 11:13 AM
publicnow.com logoMesoblast Reports on Annual and Fourth Quarter Results (NASDAQ:MESO)
www.publicnow.com - August 25 at 11:12 AM
publicnow.com logoAnnual Financial Results Presentation (NASDAQ:MESO)
www.publicnow.com - August 25 at 11:12 AM
publicnow.com logoPreliminary Final Report (Including Appendix 4E) (NASDAQ:MESO)
www.publicnow.com - August 25 at 11:12 AM
investorplace.com logoBiggest Movers in Manufacturing Stocks Now - NYMX CORI DXYN MNTA - Investorplace.com (NASDAQ:MESO)
investorplace.com - August 24 at 5:57 PM
benzinga.com logoEarnings Scheduled For August 24, 2016 - Benzinga - Benzinga (NASDAQ:MESO)
www.benzinga.com - August 24 at 9:16 AM
finance.yahoo.com logoMesoblast to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast (NASDAQ:MESO)
finance.yahoo.com - August 19 at 9:09 AM
investing.com logoAustralia stocks higher at close of trade; S&P/ASX 200 up 0.11% - Investing.com (NASDAQ:MESO)
www.investing.com - August 18 at 6:13 PM
fool.com logoASX 200 drops: 12 shares you should have been watching | Motley ... - Motley Fool Australia (NASDAQ:MESO)
www.fool.com.au - August 18 at 6:13 PM
investors.com logoMesoblast Ltd granted key U.S. patent for treating rheumatic diseases - Proactive Investors Australia (NASDAQ:MESO)
www.proactiveinvestors.com.au - August 18 at 6:13 PM
News IconBone Marrow Transplant Market Segments and Forecast By End-use Industry 2016-2026 (NASDAQ:MESO)
www.medgadget.com - August 18 at 9:15 AM
4-traders.com logoMesoblast : MSB Strengthens US Patent Portfolio For Rheumatic Diseases (NASDAQ:MESO)
www.4-traders.com - August 17 at 9:15 AM

Social

Mesoblast (NASDAQ:MESO) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff